Quest Diagnostics (DGX) Stock Buyback History
TTM buyback yield 2.09% · Shareholder yield (TTM) 2.09%.
TTM buyback yield
2.09%
Shareholder yield (TTM)
2.09%
5Y share count change
-16.9%
TTM buyback spend
$450.00M
SBC coverage (TTM)
7.38x
YoY change in spend
+198.0%
5Y CAGR of spend
+6.7%
Peak year (2021)
$2.20B
Cumulative spend
$12.59B
TTM metrics calculated from the four most recent reported quarters, ending (reported ).
Key takeaways
- Quest Diagnostics (DGX) repurchased about $450.00M of stock over the trailing twelve months.
- Diluted share count is down 16.9% over the last ~5 fiscal years — buybacks are net-shrinking the share base.
- TTM buyback ÷ stock-based-comp ratio of 7.38× — repurchases more than cover SBC dilution.
- Cash buyback spend has compounded at +6.7% per year over the latest 5-year window.
- TTM repurchases used about 46% of free cash flow remaining after dividends.
Buyback context per fiscal year
Annual repurchases alongside stock-based compensation, diluted share count and the year-over-year change — useful for SBC-coverage and dilution-offset reading at a glance.
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $450.00M | $88.00M | $362.00M | 0.11B | 0.0% | 2.34% |
| 2024 | $151.00M | $88.00M | $63.00M | 0.11B | 0.0% | 0.90% |
| 2023 | $275.00M | $77.00M | $198.00M | 0.11B | -4.2% | 1.78% |
| 2022 | $1.41B | $77.00M | $1.33B | 0.12B | -7.8% | 7.96% |
| 2021 | $2.20B | $79.00M | $2.12B | 0.13B | -5.9% | 10.42% |
| 2020 | $325.00M | $97.00M | $228.00M | 0.14B | 0.0% | 2.02% |
| 2019 | $353.00M | $56.00M | $297.00M | 0.14B | -2.2% | 2.47% |
| 2018 | $322.00M | $61.00M | $261.00M | 0.14B | -0.7% | 2.84% |
| 2017 | $465.00M | $79.00M | $386.00M | 0.14B | -1.4% | 3.47% |
| 2016 | $590.00M | $69.00M | $521.00M | 0.14B | -2.1% | 4.65% |
| 2015 | $224.00M | $52.00M | $172.00M | 0.14B | 0.0% | 2.20% |
| 2014 | $132.00M | $51.00M | $81.00M | 0.14B | -5.2% | 1.36% |
| 2013 | $1.04B | $28.00M | $1.01B | 0.15B | -4.4% | 13.27% |
| 2012 | $200.00M | $50.30M | $149.70M | 0.16B | -0.1% | 2.16% |
| 2011 | $935.00M | $71.90M | $863.10M | 0.16B | -9.6% | 10.17% |
| 2010 | $750.00M | $53.90M | $696.10M | 0.18B | -5.6% | 8.60% |
| 2009 | $499.99M | $75.10M | $424.89M | 0.19B | -4.2% | 4.60% |
| 2008 | $254.00M | $70.60M | $183.40M | 0.20B | 0.4% | 2.58% |
| 2007 | $145.66M | $0.00 | $145.66M | 0.20B | -2.1% | 1.42% |
| 2006 | $472.32M | $0.00 | $472.32M | 0.20B | -2.9% | 4.61% |
| 2005 | $390.16M | $0.00 | $390.16M | 0.21B | -3.2% | 3.82% |
| 2004 | $734.58M | $0.00 | $734.58M | 0.21B | -1.7% | 7.68% |
| 2003 | $257.55M | $0.00 | $257.55M | 0.22B | 8.4% | 3.41% |
| 2002 | $0.00 | $0.00 | $0.00 | 0.20B | 2.0% | — |
| 2001 | $1.00M | $0.00 | $1.00M | 0.20B | 3.5% | 0.01% |
| 2000 | $0.00 | $0.00 | $0.00 | 0.19B | 39.0% | — |
| 1999 | $1.10M | $0.00 | $1.10M | 0.14B | 12.5% | — |
| 1998 | $13.00M | $0.00 | $13.00M | 0.12B | 4.1% | — |
| 1997 | $0.00 | $0.00 | $0.00 | 0.12B | -1.1% | — |
| 1996 | $0.00 | $0.00 | $0.00 | 0.12B | — | — |
Cash buyback spend (USD) — annual & quarterly history
Trailing-twelve-month and per-period cash repurchases for Quest Diagnostics (DGX) from the consolidated cash flow statement (line: common stock repurchased), in USD as filed.
Cash buyback spend over time for Quest Diagnostics (DGX)
Per-period cash repurchases
Cash buyback spend annual + quarterly history for Quest Diagnostics (DGX)
| Fiscal year | Period ended | Reported | Buyback Spend | YoY | YoY change |
|---|---|---|---|---|---|
| 2025 | $450.00M | +198.0% | +$299.00M | ||
| 2024 | $151.00M | -45.1% | -$124.00M | ||
| 2023 | $275.00M | -80.5% | -$1.13B | ||
| 2022 | $1.41B | -36.0% | -$791.00M | ||
| 2021 | $2.20B | +576.6% | +$1.87B | ||
| 2020 | $325.00M | -7.9% | -$28.00M | ||
| 2019 | $353.00M | +9.6% | +$31.00M | ||
| 2018 | $322.00M | -30.8% | -$143.00M | ||
| 2017 | $465.00M | -21.2% | -$125.00M | ||
| 2016 | $590.00M | +163.4% | +$366.00M | ||
| 2015 | $224.00M | +69.7% | +$92.00M | ||
| 2014 | $132.00M | -87.3% | -$905.00M | ||
| 2013 | $1.04B | +418.5% | +$837.00M | ||
| 2012 | $200.00M | -78.6% | -$735.00M | ||
| 2011 | $935.00M | +24.7% | +$185.00M | ||
| 2010 | $750.00M | +50.0% | +$250.01M | ||
| 2009 | $499.99M | +96.8% | +$245.99M | ||
| 2008 | $254.00M | +74.4% | +$108.34M | ||
| 2007 | $145.66M | -69.2% | -$326.67M | ||
| 2006 | $472.32M | +21.1% | +$82.16M | ||
| 2005 | $390.16M | -46.9% | -$344.41M | ||
| 2004 | $734.58M | +185.2% | +$477.03M | ||
| 2003 | $257.55M | — | +$257.55M | ||
| 2002 | $0 | -100.0% | -$1.00M | ||
| 2001 | $1.00M | — | +$1.00M | ||
| 2000 | $0 | -100.0% | -$1.10M | ||
| 1999 | $1.10M | -91.5% | -$11.90M | ||
| 1998 | $13.00M | — | +$13.00M | ||
| 1997 | $0 | — | $0 | ||
| 1996 | $0 | — | — |
Quest Diagnostics (DGX) most recent annual buyback spend stands at $450.00M (2025) – surged 198.0% year-over-year.
Quest Diagnostics buyback spend compound annual growth for the 2020–2025 (5 years) window is +6.7%, with the latest reading among the more recent periods of the dataset.
Quest Diagnostics buyback spend peaked at $2.20B in 2021; the latest annual figure is $450.00M in 2025 (79.5% below peak).
The dataset's maximum buyback spend sits at $2.20B (2021); the minimum reading of $0 dates to 1996.
Among 8 Healthcare peers, Quest Diagnostics (DGX) ranks 8th; the peer median for buyback spend is $2.75B.
Quest Diagnostics Buyback Spend 2025: $450.00M
Quest Diagnostics buyback spend in 2025 was $450.00M, surged 198.0% from 2024.
Quest Diagnostics Buyback Spend 2024: $151.00M
Quest Diagnostics buyback spend in 2024 was $151.00M, plunged 45.1% below 2023.
Quest Diagnostics Buyback Spend 2023: $275.00M
Quest Diagnostics buyback spend in 2023 was $275.00M, plunged 80.5% below 2022.
Quest Diagnostics Buyback Spend 2022: $1.41B
Quest Diagnostics buyback spend in 2022 was $1.41B, plunged 36.0% below 2021.
Quest Diagnostics Buyback Spend 2021: $2.20B
Quest Diagnostics buyback spend in 2021 was $2.20B.
See more financial history for Quest Diagnostics (DGX).
Sector peers by buyback spend
Companies in the same sector as Quest Diagnostics, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group (UNH) | $5.54B | Healthcare |
| Merck & Co. (MRK) | $5.08B | Healthcare |
| Eli Lilly (LLY) | $4.11B | Healthcare |
| Novo Nordisk (NVO) | $1.39B | Healthcare |
| AbbVie (ABBV) | $980.00M | Healthcare |
| AstraZeneca (AZN) | $719.66M | Healthcare |
| Amgen (AMGN) | $0 | Healthcare |
Share count history
Diluted weighted-average shares drive the EPS denominator and per-share capital-return maths. A falling diluted share count means buybacks are outpacing dilution from stock-based compensation and option exercises.
Diluted vs basic shares (annual)
Year-over-year change in diluted shares
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield over time
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Buybacks vs stock-based compensation
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 7.38×.
Capital allocation mix
How Quest Diagnostics splits cash returned to shareholders between dividends and buybacks, plus the headroom on free cash flow that's still available for additional repurchases.
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $969.00M (TTM FCF − TTM dividends, clamped at zero).
Data & methodology
Where do buyback, dividend and compensation figures come from?
Cash buyback spend (common stock repurchased), dividends paid and stock-based compensation come from Quest Diagnostics's consolidated cash flow statements — quarterly 10-Q and annual 10-K SEC filings, in USD as reported.
How are diluted shares and yields calculated?
Diluted weighted-average share counts come from the income statement (EPS denominator). Trailing twelve-month (TTM) aggregates sum the four most recent reported quarters. Buyback and dividend yields divide TTM cash flows by market capitalisation at the latest quarter-end.
How is buyback capacity defined?
Capacity compares TTM repurchases to free cash flow after dividends: operating cash flow minus capital expenditure, minus dividends paid, versus actual buybacks over the same trailing window.
Is this investment advice?
No. Figures are for informational and educational use only. Past buybacks and dividends do not predict future returns.
Frequently asked questions
Does Quest Diagnostics buy back its own stock?
Yes, Quest Diagnostics (DGX) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
How much does Quest Diagnostics spend on share buybacks?
Trailing twelve months (TTM) buyback spend is about $450.00M (sum of the last four quarterly cash-flow periods in our data). Figures are illustrative; verify in filings.
What is Quest Diagnostics's buyback yield?
TTM buyback yield is about 2.09% (TTM buyback spend divided by market cap at the latest quarter-end in our data).
What is Quest Diagnostics's shareholder yield?
Shareholder yield combines dividend yield and buyback yield. For the latest period we show approximately 2.09% combined (TTM-based where available).
Is Quest Diagnostics diluting shareholders?
Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has Quest Diagnostics's share count changed?
Diluted weighted average shares changed by about -16.9% over roughly five fiscal years (annual income statement data).
What is Quest Diagnostics's buyback spend?
Latest reported buyback spend for Quest Diagnostics (DGX) is $450.00M (period ending March 31, 2026).
How has Quest Diagnostics buyback spend changed year-over-year?
Quest Diagnostics (DGX) buyback spend changed +198.0% year-over-year on the latest annual filing.
What is the long-term growth rate of Quest Diagnostics buyback spend?
Quest Diagnostics (DGX) buyback spend compound annual growth rate is +6.7% over the most recent 5 years available.
When did Quest Diagnostics buyback spend hit its highest annual value?
Quest Diagnostics buyback spend reached its highest annual value of $2.20B in 2021.
What was Quest Diagnostics buyback spend in 2024?
Quest Diagnostics (DGX) buyback spend in 2024 was $151.00M.
What was Quest Diagnostics buyback spend in 2025?
Quest Diagnostics (DGX) buyback spend in 2025 was $450.00M.
Explore more
DGX Overview
Company profile, financial tools, and key metrics
DGX Revenue Counter
Earns $357.62 every second. See per minute, hour, and day.
DGX Earnings Counter
Earns $32.47 per second net profit. See per minute, hour, and day.
DGX Economic Scale
Exceeds Monaco's GDP. Compare with world economies.
DGX What If Invested
What if you had invested $1,000? See historical returns from any date.
DGX How It Makes Money
Discover visual breakdown of $11.28B in revenue — where it comes from and where it goes.
DGX Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
DGX Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
DGX Daily Price Character
Steady · 50.6% historical win rate (green days). Streaks & record days.
DGX Stock Split History
2 splits on record. Dates, ratios, and cumulative multiple.
DGX Dividend Profile
Yield: 1.68%. Safety: 5/8. See full history.
DGX Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
DGX Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.
DGX Dividend Capture
Historical pre-ex touch stats, gap distribution, after-tax calculator, and a backtest simulator (limit-order vs MOC exit).
DGX Financials
Revenue, EPS, EBITDA, market cap, debt and balance sheet history with annual and quarterly data.